FDA Approves New Oral Pellet Formulation for Hereditary Angioedema Treatment

AI-generated NewsSnap summary based on source reporting.
Published: 2026-10-21
Category: health
Source: BioSpace
Original source

The FDA has approved BioCryst Pharmaceuticals' ORLADEYO® 150 mg oral pellet formulation. This new option for adults and adolescents aged 12 and older with Hereditary Angioedema (HAE) offers an alternative for patients who struggle with swallowing capsules, expanding prophylactic treatment choices.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai